Serum levels of HE4 and SCCAg and their relationships with biological behavior of endometrial carcinoma

doi:10.3969/j.issn.1673-8640.2014.05.013

Abstract

Abstract: Objective To investigate human epididymal secretory protein 4 (HE4) and squamous cell carcinoma antigen (SCCAg) levels in endometrial carcinoma and their relationships with biological behavior of endometrial carcinoma. Methods Serum levels of HE4 and SCCAg were detected by enzyme-linked immunosorbent assay in 85 patients with endometrial carcinoma, 30 patients with endometrial atypical hyperplasia and 30 healthy women (control group). The clinical signicance of HE4 and SCCAg were analyzed comparatively. Results Serum levels of HE4 and SCCAg were (199.6 ± 31.2) pmol/L and 0.98(0.15-4.85) μg/L in patients with endometrial carcinoma, which were higher than those in patients with endometrial atypical hyperplasia [(91.6 ± 16.8) pmol/L and 0.18(0.02-1.41) μg/L, P<0.05] and control group [(82.5 ± 9.7) pmol/L and 0.13(0.03-1.32) μg/L, P<0.05]. The diagnosis sensitivities of HE4 and SCCAg for the diagnosis of endometrial carcinoma were 63.5% and 14.1%, and the specificities were 96.7% and 100.0%. Serum HE4 and SCCAg levels and the positive rates had increasing trend with stage rising, and the positive rates in advanced stages of endometrial carcinoma (HE4: 90.0% for stage Ⅲ and 100.0% for stage Ⅳ, SCCAg: 30.0% for stage Ⅲ and 25.0% for stage Ⅳ), which were higher than those in early stage(61.1% and 5.6% for stage Ⅰ, P<0.05). For different clinical pathological factors, the positive rate of HE4 in non-endometrial adenocarcinoma was up to 92.0%, which was higher than that in endometrial adenocarcinoma (51.7%, P<0.05). HE4 expression in endometrial carcinoma had the relationship with tumor size, pathological type, depth of tumor invasion and tumor metastasis (P<0.05), and SCCAg expression in endometrial carcinoma had the relationship with tumor metastasis only (P<0.01). Conclusions Serum HE4 has clinical early diagnosis and identification significance for endometrial carcinoma, and it can be used as an indicator for monitoring endometrial carcinoma. However, SCCAg had a little diagnosis significance for the diagnosis of endometrial carcinoma. It only has a certain significance in the course of monitoring and tumor metastasis identification.

Key words: Human epididymal secretory protein 4, Squamous cell carcinoma antigen, Endometrial carcinoma, Malignant tumor

CLC Number:

R446.62

LAO Ming, WU Yun, ZHU Bo, HUANG Wencheng, HUANG Lingsha, WANG Ying, LI Meiqin, ZHU Chunyan, LIU Jinfeng.. Serum levels of HE4 and SCCAg and their relationships with biological behavior of endometrial carcinoma[J]. , 2014, 29(5): 488-491.

References

[1] 刘颖, 韩秋峪, 刘慧, 等.子宫内膜癌中C-erbB-2、Ki-67表达及血清CA125水平与临床病理特征的关系[J].放射免疫学杂志, 2010, 23(4):419-421.
[2] 丛培珊, 孙桂荣, 张娜娜, 等.人附睾蛋白4对子宫内膜癌和卵巢癌早期辅助诊断价值的评估[J].检验医学, 2011, 26(7): 447-451.
[3] Hellstrm I, Raycraft J, Hayden-Ledbetter M, et al.The HFA(WFDC2)protein is a biomarker for ovarian carcinoma[J].Cancer Res, 2003, 63(13):3695-3700.
[4] Galgano MT, Hampton GM, Frierson HF Jr.Comprehensive analysis of HE4 expression in normal and malignant human tissues[J].Mod Pathol, 2006, 19(6):847-853.
[5] Fejzo MS, Dering J, Ginther C, et al. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target[J].Genes Chromosomes Cancer, 2008, 47(10):873-883.
[6] Anderson GL, Mclntosh M, Wu L, et al.Assessing lead time of selected ovarian cancer biomarker:a nested case-control study[J].J Natl Cancer Inst, 2010, 102(1):26-38.
[7] Moore RG, Brown AK, Miller MC, et al.Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus[J].Gynecol Oncol, 2008, 110(2):196-201.
[8] 马荣, 耿晓星, 唐丽萍, 等. 人附睾分泌蛋白4检测对子宫内膜癌的诊断及预后的意义[J].临床肿瘤学杂志, 2011, 16(9):790-793.
[9] 李卫鹏, 张蕾蕾.鳞状细胞癌抗原研究进展[J].放射免疫学杂志, 2010, 23(1):34-37.
[10] 吕秋波, 申桂华, 伍凤莉, 等. 血清CA125、CA19-9、CEA及SCC水平在子宫内膜癌患者中的诊断意义[J].中国肿瘤临床, 2002, 29(9):638-640.
[11] Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4(HE4)is a secreted glycolprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res, 2005, 65(6):2162-2169.